Form 4: Teladoc Health Executive Adam Vandervoort Reports Stock Transactions
SEC Form 4 Filing
Adam Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including restricted stock units and performance stock units.
Summary
- Adam Vandervoort, the Chief Legal Officer and Secretary of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership.
- The transactions include the acquisition of common stock through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- Vandervoort acquired 1,881 shares on February 28, 2025, through RSU conversions, and another 4,418 shares on March 28, 2025, also from RSU conversions.
- Additionally, 1,505 shares were acquired on February 28, 2025, through PSU conversions.
- A sale of 3,935 shares occurred on March 3, 2025, at a price of $9.684 per share to cover tax withholding obligations related to the vesting of RSUs and PSUs.
- Following these transactions, Vandervoort directly owns 53,919 shares of Teladoc Health common stock and holds 17,672 restricted stock units and 6,025 performance stock units.
- He was also granted 109,832 restricted stock units on March 1, 2025, which vest over time.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. The sale of shares to cover taxes is a common practice and doesn't necessarily indicate a lack of confidence in the company.
Positives
- The vesting of restricted stock units and performance stock units indicates that Vandervoort is meeting performance criteria or time-based vesting requirements, which could be seen as a positive sign.
Negatives
- The sale of 3,935 shares to cover tax obligations, while common, could be interpreted negatively if investors believe the executive is reducing their stake in the company.
Risks
- Executive stock sales can sometimes be perceived negatively by the market, potentially leading to short-term price fluctuations.
- The vesting schedule of the restricted stock units and performance stock units could create ongoing selling pressure if Vandervoort continues to sell shares to cover tax obligations.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's confidence in the company's future prospects. However, sales to cover tax obligations are generally viewed as routine.
Comparison to Industry Standards
- Executive compensation packages in the telehealth industry often include a mix of salary, stock options, restricted stock units, and performance-based incentives.
- Vesting schedules for RSUs and PSUs are typically structured to align executive interests with long-term shareholder value, often vesting over a period of 3-4 years with quarterly or annual installments.
- Compared to peers like Amwell or similar tech companies, Teladoc's executive compensation structure appears standard, with a focus on equity-based compensation to incentivize performance and retention.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 2022-03-01 | Reporting person was granted 22,571 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 2023-03-03 | Reporting person was granted 53,013 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 2024-03-01 | Reporting person earned 18,067 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 2025-02-28 | Acquisition of 1,881 shares through RSU conversion. |
| 2025-02-28 | Acquisition of 1,505 shares through PSU conversion. |
| 2025-03-01 | Reporting person was granted 109,832 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 2025-03-03 | Sale of 3,935 shares at $9.684 per share. |
| 2025-03-28 | Acquisition of 4,418 shares through RSU conversion. |
| 2025-03-04 | Date of Form 4 filing. |
Keywords
Teladoc Health, TDOC, Adam Vandervoort, Form 4, Stock Transactions, Restricted Stock Units, Performance Stock Units, Beneficial Ownership, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.